- Home
- PRFX vs CMND Comparison
PRFX vs CMND Comparison
Compare PRFX & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRFX | CMND |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6M | 1.4M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PRFX | CMND |
|---|---|---|
| Price | $2.55 | $1.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 344.5K | 99.2K |
| Earning Date | 03-26-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.58 | $0.07 |
| 52 Week High | $3.71 | $3.25 |
Technical Indicators
Market Signals| Indicator | PRFX | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 56.63 | 60.98 |
| Support Level | $1.28 | $0.99 |
| Resistance Level | $2.91 | $1.27 |
| Average True Range (ATR) | 0.30 | 0.11 |
| MACD | 0.05 | 0.07 |
| Stochastic Oscillator | 75.08 | 82.32 |
Price Performance
Historical ComparisonAbout PRFX PainReform Ltd.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasise reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the Company's lead product, is based on the local anaesthetic ropivacaine and targets the postoperative pain relief market.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.